Antibody Therapy as a Future Treatment Option for Ebola Virus Infection

• Sanchez A , GeisbertTW, FeldmannH: Filoviridae: Marburg and Ebola viruses. In: Fields Virology 5th Edition. Knipe DM, Howley PM (Eds.), Lippincott-Williams & Wilkins, PA, USA 1409–1448 (2007).
   Google Scholar
• Geisbert TW , HensleyLE: Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.Expert Rev. Mol. Med.6(20), 1–24 (2004).
   PubMedGoogle Scholar
• Leroy EM , KumulunguiB, PourrutXet al.: Fruit bats as reservoirs of Ebola virus.Nature438(7068), 575–576 (2005).
   PubMed Web of Science ®Google Scholar
• Alvarez CP , LasalaF, CarrilloJet al.: C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.J. Virol.76(13), 6841–6844 (2002).
   PubMed Web of Science ®Google Scholar
• Chan SY , EmpigCJ, WelteFJet al.: Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.Cell106(1), 117–126 (2001).
   PubMed Web of Science ®Google Scholar
• Shimojima M , TakadaA, EbiharaHet al.: Tyro3 family-mediated cell entry of Ebola and Marburg viruses.J. Virol.80(20), 10109–10116 (2006).
   PubMed Web of Science ®Google Scholar
• Takada A , FujiokaK, TsuijiMet al.: Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.J. Virol.78(6), 2943–2947 (2004).
   PubMed Web of Science ®Google Scholar
• Takada A , WatanabeS, ItoHet al.: Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry.Virology278(1), 20–26 (2000).
   PubMed Web of Science ®Google Scholar
• Takada A , KawaokaY: Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.Rev. Med. Virol.13(6), 387–398 (2003).
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M , ChenL, SchmaljohnAL: How Ebola and Marburg viruses battle the immune system.Nat. Rev. Immunol.7(7), 556–567 (2007).
   PubMed Web of Science ®Google Scholar
• Ito H , WatanabeS, TakadaA, KawaokaY: Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.J. Virol.75(3), 1576–1580 (2001).
   PubMed Web of Science ®Google Scholar
• Dolnik O , VolchkovaV, GartenWet al.: Ectodomain shedding of the glycoprotein GP of Ebola virus.Embo J.23(10), 2175–2184 (2004).
   PubMed Web of Science ®Google Scholar
• Reed DS , MohamadzadehM: Status and challenges of filovirus vaccines.Vaccine25(11), 1923–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Bukreyev A , RollinPE, TateMKet al.: Successful topical respiratory tract immunization of primates against Ebola virus.J. Virol.81(12), 6379–6388 (2007).
   PubMed Web of Science ®Google Scholar
• Jones SM , FeldmannH, StroherUet al.: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Nat. Med.11(7), 786–790 (2005).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ , SanchezA, RollinPE, YangZY, NabelGJ: Development of a preventive vaccine for Ebola virus infection in primates.Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Olinger GG , BaileyMA, DyeJMet al.: Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.J. Virol.79(22), 14189–14196 (2005).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ , GeisbertT, GeisbertJet al.: Mechanism of immune protection against Ebola virus infection in non-human primates. Presented at: XIII International Conference on Negative Strand Viruses. Salamanca, Spain, 21 June 2006.
   Google Scholar
• Sullivan NJ , GeisbertTW, GeisbertJBet al.: Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.PLoS Med.3(6), e177 (2006).
   PubMed Web of Science ®Google Scholar
• Maruyama T , RodriguezLL, JahrlingPBet al.: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol.73(7), 6024–6030 (1999).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , HensleyLE, GeisbertJB, JahrlingPB: Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.Virology293(1), 15–19 (2002).
   PubMed Web of Science ®Google Scholar
• Takada A , EbiharaH, FeldmannF, GeisbertTW, KawaokaY: Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. (2007) (In press)
   PubMed Web of Science ®Google Scholar
• Emond RT , EvansB, BowenET, LloydG: A case of Ebola virus infection.Br. Med. J.2(6086), 541–544 (1977).
   PubMed Web of Science ®Google Scholar
• Mupapa K , MassambaM, KibadiKet al.: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients.J. Infect. Dis.179(Suppl. 1), S18–S23 (1999).
   PubMed Web of Science ®Google Scholar
• Sadek RF , KhanAS, StevensG, PetersCJ, KsiazekTG: Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.J. Infect. Dis.179(Suppl. 1), S24–S27 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta M , MahantyS, BrayM, AhmedR, RollinPE: Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.J. Virol.75(10), 4649–4654 (2001).
   PubMed Web of Science ®Google Scholar
• Jahrling PB , GeisbertTW, GeisbertJBet al.: Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections.J. Infect. Dis.179(Suppl. 1), S224–234 (1999).
   PubMed Web of Science ®Google Scholar
• Kudoyarova-Zubavichene NM , SergeyevNN, ChepurnovAA, NetesovSV: Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J. Infect. Dis.179(Suppl. 1), S218–S223 (1999).
   PubMed Web of Science ®Google Scholar
• Borisevich IV , MikhailovVV, KrasnianskiiVPet al.: Development and study of the properties of immunoglobulin against Ebola fever. Vopr. Virusol.40(6), 270–273 (1995).
   PubMedGoogle Scholar
• Mikhailov VV , BorisevichIV, Chernikova NK, PotryvaevaNV, KrasnianskiiVP: The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr. Virusol.39(2), 82–84 (1994).
   PubMed Web of Science ®Google Scholar
• Jahrling PB , GeisbertJ, SwearengenJRet al.: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. (Suppl. 11), S135–S140 (1996).
   Web of Science ®Google Scholar
• Takada A , FeldmannH, KsiazekTG, KawaokaY: Antibody-dependent enhancement of Ebola virus infection.J. Virol.77(13), 7539–7544 (2003).
   PubMed Web of Science ®Google Scholar
• Takada A , WatanabeS, OkazakiK, KidaH, KawaokaY: Infectivity-enhancing antibodies to Ebola virus glycoprotein.J. Virol.75(5), 2324–2330 (2001).
   PubMed Web of Science ®Google Scholar
• Takada A , EbiharaH, JonesS, FeldmannH, KawaokaY: Protective efficacy of neutralizing antibodies against Ebola virus infection.Vaccine25(6), 993–999 (2007).
   PubMed Web of Science ®Google Scholar
• Takada A , FeldmannH, StroeherUet al.: Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.J. Virol.77(2), 1069–1074 (2003)
   PubMed Web of Science ®Google Scholar
• Lefranc MP , GiudicelliV, KaasQet al.: IMGT, the international ImMunoGeneTics information system.Nucleic. Acids. Res.33(Database issue), D593–D597 (2005).
   PubMed Web of Science ®Google Scholar
• Druar C , SainiSS, CossittMAet al.: Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus soluble glycoprotein.Immunogenetics57(10), 730–738 (2005).
   PubMed Web of Science ®Google Scholar
• Maruyama T , ParrenPW, SanchezAet al.: Recombinant human monoclonal antibodies to Ebola virus.J. Infect. Dis.179(Suppl. 1), S235–S239 (1999).
   PubMed Web of Science ®Google Scholar
• Shahhosseini S , DasD, QiuXet al.: Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.J. Virol. Methods143(1), 29–37 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson JA , HeveyM, BakkenRet al.: Epitopes involved in antibody-mediated protection from Ebola virus.Science287(5458), 1664–1666 (2000).
   PubMed Web of Science ®Google Scholar
• Parren PW , GeisbertTW, MaruyamaT, JahrlingPB, BurtonDR: Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.J. Virol.76(12), 6408–6412 (2002).
   PubMed Web of Science ®Google Scholar
• Oswald WB , GeisbertTW, DavisKJet al.: Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.PLoS Pathog.3(1), E9 (2007).
   PubMed Web of Science ®Google Scholar
• Hevey M , NegleyD, SchmaljohnA: Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes.Virology314(1), 350–357 (2003).
   PubMed Web of Science ®Google Scholar
• Cardenas WB , LooYM, GaleMJr, et al. : Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol.80(11), 5168–5178 (2006).
   PubMed Web of Science ®Google Scholar
• Feng Z , CervenyM, YanZ, HeB: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.J. Virol.81(1), 182–192 (2007).
   PubMed Web of Science ®Google Scholar
• Reid SP , LeungLW, HartmanALet al.: Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.J. Virol.80(11), 5156–5167 (2006).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , YoungHA, JahrlingPBet al.: Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.J. Infect. Dis.188(11), 1618–1629 (2003).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , HensleyLE, JahrlingPBet al.: Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.Lancet362(9400), 1953–1958 (2003).
   PubMed Web of Science ®Google Scholar
• Mahanty S , HutchinsonK, AgarwalSet al.: Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.J. Immunol.170(6), 2797–2801 (2003).
   PubMed Web of Science ®Google Scholar
• Bosio CM , AmanMJ, GroganCet al.: Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.J. Infect. Dis.188(11), 1630–1638 (2003).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , HensleyLE, GibbTRet al.: Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.Lab. Invest.80(2), 171–186 (2000).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , HensleyLE, LarsenTet al.: Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.Am. J. Pathol.163(6), 2347–2370 (2003).
   PubMed Web of Science ®Google Scholar

Website

• Yan W, Lisa T, Marie-Paule L: IMGT, the international ImMunoGenetics information system® (Accessed August2007). http://imgt.cines.fr/textes/IMGTrepertoire/GenesClinical/monoclonalantibodies/
   Google Scholar